Cited 13 times in
Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2014-12-18T08:36:20Z | - |
dc.date.available | 2014-12-18T08:36:20Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86618 | - |
dc.description.abstract | In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chemoembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an an-tiangiogenic therapy. Radioembolization with yttrium-90 (90Y) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that 90Y radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after 90Y therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of 90Y radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yun Hwan Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.identifier.doi | 10.1159/000345887 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | Hepatocellular carcinoma ; Yttrium-90 ; Transarterial chemoembolization | - |
dc.identifier.url | http://www.karger.com/Article/FullText/345887 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Yttrium-90 | - |
dc.subject.keyword | Transarterial chemoembolization | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 84 | - |
dc.citation.number | suppl1 | - |
dc.citation.startPage | 34 | - |
dc.citation.endPage | 39 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.84(suppl1) : 34-39, 2013 | - |
dc.identifier.rimsid | 29096 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.